Skip to main content
Evidence Snapshot

C-8 sterol isomerase ERG2

CHEMBL3224 SINGLE PROTEIN Saccharomyces cerevisiae S288c
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:13:19Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3224
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats C-8 sterol isomerase ERG2 as ChEMBL target CHEMBL3224, mapped to UniProt P32352. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
C-8 sterol isomerase ERG2
SINGLE PROTEIN · Saccharomyces cerevisiae S288c
As of 2026-09-13
ChEMBL target ID
CHEMBL3224
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P32352
C-8 sterol isomerase ERG2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why C-8 sterol isomerase ERG2 matters

As of 2026-09-13

C-8 sterol isomerase ERG2 is reviewed as C-8 sterol isomerase ERG2 (UniProt P32352); the current evidence base includes 10 approved drugs, 68 compounds, and 11 assays, with lead potency reaching pChEMBL 10.3.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 68 compounds, and 11 assays for this target. The dominant activity type is KI. CHEMBL372700 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL372700 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why C-8 sterol isomerase ERG2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P32352, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

68
Total Compounds
11
Total Assays
10
Approved Drugs
KI: 43.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL372700
 10.3 Ki —
No preferred name
CHEMBL365842
 10.1 Ki —
No preferred name
CHEMBL15023
 9.8 Ki Clinical
No preferred name
CHEMBL365141
 9.7 Ki —
No preferred name
CHEMBL17470
 9.4 Ki —

Approved Drugs

Structure Compound First Approval
RALOXIFENE
CHEMBL81
 1997
NAFTIFINE
CHEMBL626
 1988
AMIODARONE
CHEMBL633
 1985
HALOPERIDOL
CHEMBL54
 1967
TRIFLUOPERAZINE
CHEMBL422
 1959
TRIPARANOL
CHEMBL187709
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:13:19Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3224